Search results

Filters

  • Journals
  • Authors
  • Keywords
  • Date
  • Type

Search results

Number of results: 1
items per page: 25 50 75
Sort by:
Download PDF Download RIS Download Bibtex

Abstract

Pellagra is a rare disease caused by niacin deficiency or a disruption of its metabolism. Its manifestations are dermatitis with pronounced photosensitivity, gastrointestinal symptoms, and neuropsychiatric ailments. Currently pellagra is developed in people who chronically abuse alcohol or are treated with medications from specific pharmacological groups (immunosuppressive and anti-tuberculosis drugs).
Although the root cause of the disease was established in the mid-twentieth century, a detailed explanation of the processes leading to the development of symptoms has not yet been proposed. They include complex abnormalities at the molecular, metabolic, and immunological levels. Diagnostics is based primarily on the clinical presentation of the disease, while auxiliary tests play secondary role. The low prevalence of the disease, meaning that physicians are unfamiliar with its re-cognition, often leads to delays in diagnosis and appropriate treatment. The therapy is causal and based on administering niacinamide. Failure to implement treatment in the early stages of the disease leads to the patient’s death.
The aim of this literature review is to summarize the current state of knowledge on the pathomechanisms of pellagra, highlighting the clinical implications, and key elements of diagnostic and therapeutic manage-ment that are important in the treatment of pellagra patients.
Go to article

Bibliography

1. Karthikeyan K., Thappa D.M.: Pellagra and skin. Int J Derm. 2002; 41 (8): 476–481.
2. Cao S., Wang X., Cestodio K.: Pellagra, an Almost-Forgotten Differential Diagnosis of Chronic Diarrhea: More Prevalent Than We Think. Nutrition in Clinical Practice. Nutr Clin Pract. 2019; 35 (5): 860–863.
3. Hegyi J., Schwartz R.A., Hegyi V.: Pellagra: Dermatitis, dementia, and diarrhea. Int J Derm. 2004; 43 (1): 1–5.
4. Prinzo Z.W.: Pellagra and its prevention and control in major emergencies. WHO. 2000; NHD/00.01: 1–32.
5. Narasimha V.L., Ganesh S., Reddy S., et al.: Pellagra and Alcohol Dependence Syndrome: Findings From a Tertiary Care Addiction Treatment Centre in India. MCA. 2019; 54 (2): 148–151.
6. Redzic S., Gupta V.: Niacin Deficiency. StatPearls 2021.
7. Elvehjem C.A., Madden R.J., Strong F.M., Woolley D.W.: Relation of Nicotinic Acid And Nicotinic Acid Amide To Canine Black Tongue. J Am Chem Soc. 1937; 59 (9): 1767–1768.
8. Stratigos J.D., Katsambas A.: Pellagra: a still existing disease. Br J Dermatol. 1977; 96 (1): 99–106.
9. Tymoczko J.L., Berg J.M., Stryer L.: Biochemistry. A Short Course. W.H. Freeman Company 2013.
10. Jacobson M.K., Jacobson E.L.: Vitamin B3 in Health and Disease: Toward the Second Century of Discovery. In: Methods in Molecular Biology. Methods Mol Biol. 2018; 1813: 3–8.
11. Horwitt M.K., Harvey C.C., Rothwell W.S., Cutler J.L., Haffron D.: Tryptophan-Niacin Relationships in Man. J Nutr. 1956; 60 (Suppl. 1): 1–43.
12. Badawy A.A.-B.: Pellagra and Alcoholism: A Biochemical Perspective. Alcohol Alcohol. 2014; 49 (3): 238–250.
13. Carpenter K.J.: The Relationship of Pellagra to Corn and the Low Availability of Niacin in Cereals. Experientia Suppl. 1983; 44: 197–222.
14. Judd L.E., Poskitt B.L.: Pellagra in a patient with an eating disorder. Br J Dermatol. 1991; 125 (1): 71–72.
15. Yamaguchi S., Miyagi T., Sogabe Y., et al.: Depletion of Epidermal Langerhans Cells in the Skin Lesions of Pellagra Patients. Am J Dermatopath. 2017; 39 (6): 428–432.
16. Kipsang J.K., Choge J.K., Marinda P.A., Khayeka-Wandabwa C.: Pellagra in isoniazid preventive and antiretroviral therapy. IDCases. 2019; 17: e00550.
17. Chauchan R., Vyas P., Mabena D.: Pellagra in an HIV-infected Individual: a Cause of Chronic Diarrhoea. Med J Armed Forces India. 1997; 53 (4): 303–304.
18. Murray R.K., Granner D.K., Rodwell V.W.: Harper’s Illustrated Biochemistry, Twenty-Seventh Edition. The McGraw-Hill Companies 2012.
19. Shah G.M., Shah R.G., Veillette H., Kirkland J.B., Pasieka J.L., Warner R.R.P.: Biochemical Assessment of Niacin Deficiency Among Carcinoid Cancer Patients. Am J Gastroenterol. 2005; 100 (10): 2307– 2314.
20. Periyasamy S., John S., Padmavati R., et al.: Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study. JAMA Psychiatry. 2019; 76 (10): 1026–1034.
21. Sugita K., Ikenouchi-Sugita A., Nakayama Y., et al.: Prostaglandin E2 is critical for the development of niacin-deficiency-induced photosensitivity via ROS production. Sci Rep. 2013; 3 (1): 2973.
22. Wan P., Moat S., Anstey A.: Pellagra: a review with emphasis on photosensitivity. Br J Dermatol. 2011; 164 (6): 1188–1200.
23. Taylor R.G., Levy H.L., McInnes R.R.: Histidase and histidinemia. Clinical and molecular considerations. Mol Biol Med. 1991; 8 (1): 101–116.
24. Beretich G.R. Jr.: Do high leucine/low tryptophan dieting foods (yogurt, gelatin) with niacin supplementation cause neuropsychiatric symptoms (depression) but not dermatological symptoms of pellagra? Med Hypotheses. 2005; 65 (3): 628–629.
25. Savvidou S.: Pellagra: A Non-Eradicated Old Disease. Clin Pract. 2014; 4 (1): 637.
26. Duncan K.O., Bolognia J.L., Schaffer J.V., Ko C.J.: Dermatology Essentials. Elsevier 2014.
27. Crook M.A.: The importance of recognizing pellagra (niacin deficiency) as it still occurs. Nutrition. 2014; 30 (6): 729–730.
28. Szepietowski J., Wiśnicka B.: Zmiany skórne u chorych z zespołami otępiennymi. Polska Medycyna Paliatywna. 2004; 3 (1): 33–37.
29. Tadil S., Darla R.: Pemphigus Pellagrosus masquerading as cutaneous adverse drug reaction. Int J Derm. 2020; 2 (1): 34–37.
30. Zhang X.-J., Wang A.-P., Shi T.-Y., et al.: The psychosocial adaptation of patients with skin disease: a scoping review. BMC Public Health. 2019; 19: 1404.
31. Roosta N., Black D., Peng D., Riley L.: Skin disease and stigma in emerging adulthood: impact on healthy development. J Cutan Med Surg. 2010; 14 (6): 285–290.
32. Yuksel P.E., Sen. S., Aydin F., Senturk N., Sen N., Cengiz N., et al.: Phenobarbital-induced pellagra resulted in death. Cutan Ocul Toxicol. 2013; 33 (1): 76–78.
33. Mousa T.Y., Mousa O.Y.: Nicotinic Acid Deficiency. StatPearls 2020. 34. Wei W., Bo L.: Case report of mental disorder induced by niacin deficiency. Shanghai Arch Psychiatry. 2012; 24 (6): 352–354.
35. Niacin. Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/ (access on 1st February 2021).
36. Piqué-Duran E., Pérez-Cejudo J.A., Cameselle D., Palacios-Llopis S., García-Vázquez O.: Pellagra: A Clinical, Histopathological, and Epidemiological Study of 7 Cases. Actas Dermosifiliogr. 2012; 103 (1): 51–58.
37. Frank G.P., Voorend D.M., Chamdula A., van Oosterhout J.J., Koop K.: Pellagra: A non-communicable disease of poverty. Trop Doct. 2012; 42 (3): 182–184.
38. Milovanović D., Djukić A., Stepanović R., Peković D., Vranjesecić D.: [Hatnup disease (report of 2 cases in one family)]. Srp Arh Celok Lek. 2000; 128 (3–4): 97–103.
39. Vanucchi H., Favaro F.M., Cunha D.F., Marchini J.F.: Assessment of zinc nutritional status of pellagra patients. Alcohol Alcohol. 1995; 30 (3): 297–302.
40. Wang S.Q., Balagula Y., Osterwalder U.: Photoprotection: a Review of the Current and future Technologies. Dermatol Ther. 2010; 23 (1): 31–47.
41. Pellagra Treated With Tryptophan. Nutr Rev. 1987; 45 (7): 142–148.
42. Allen J.A., Peterson A., Sufit R., et al.: Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum. 2011; 63 (11): 3633–3639.
43. Burgdorf W.H.C., Plewig G., Wolff H.H., Landthaler M.: Dermatologia Braun-Falco. Wydawnictwo Czelej 2017. 44. Bilgili S.G., Karadag A.S., Calka O., Altun F.: Isoniazid-induced pellagra. Cutan Ocul Toxicol. 2011; 30 (4): 317–319.
Go to article

Authors and Affiliations

Przemysław Hałubiec
1
ORCID: ORCID
Monika Leończyk
1
Filip Staszewski
1
Monika Łazarczyk
1
Andrzej Kazimierz Jaworek
1
Anna Wojas-Pelc
1

  1. Department of Dermatology, Jagiellonian University Medical College, Kraków, Poland

This page uses 'cookies'. Learn more